These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 29674328)

  • 21. Treprostinil for the treatment of pulmonary arterial hypertension.
    Torres F; Rubin LJ
    Expert Rev Cardiovasc Ther; 2013 Jan; 11(1):13-25. PubMed ID: 23259441
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transition From Subcutaneous or Inhaled Treprostinil to Oral Treprostinil at Home in Patients With Pulmonary Arterial Hypertension: A Retrospective Case Series.
    Ackerbauer KA; Tandon R
    J Pharm Pract; 2018 Apr; 31(2):163-166. PubMed ID: 28464760
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhaled treprostinil for the treatment of pulmonary arterial hypertension.
    LeVarge BL; Channick RN
    Expert Rev Respir Med; 2012 Jun; 6(3):255-65. PubMed ID: 22788940
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dose proportionality of treprostinil sodium administered by continuous subcutaneous and intravenous infusion.
    McSwain CS; Benza R; Shapiro S; Hill N; Schilz R; Elliott CG; Zwicke DL; Oudiz RJ; Staszewski JP; Arneson CP; Wade M; Zaccardelli D; McLaughlin V
    J Clin Pharmacol; 2008 Jan; 48(1):19-25. PubMed ID: 18094217
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension.
    Benza RL; Seeger W; McLaughlin VV; Channick RN; Voswinckel R; Tapson VF; Robbins IM; Olschewski H; Rubin LJ
    J Heart Lung Transplant; 2011 Dec; 30(12):1327-33. PubMed ID: 22055098
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety, Tolerability and Clinical Effects of a Rapid Dose Titration of Subcutaneous Treprostinil Therapy in Pulmonary Arterial Hypertension: A Prospective Multi-Centre Trial.
    Grünig E; Benjamin N; Lange TJ; Krueger U; Klose H; Neurohr C; Wilkens H; Halank M; Seyfarth HJ; Held M; Traube A; Pernow M; Grover ER; Egenlauf B; Gerhardt F; Viethen T; Rosenkranz S
    Respiration; 2016; 92(6):362-370. PubMed ID: 27784026
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Subcutaneous treprostinil for pulmonary hypertension in chronic lung disease of infancy.
    Ferdman DJ; Rosenzweig EB; Zuckerman WA; Krishnan U
    Pediatrics; 2014 Jul; 134(1):e274-8. PubMed ID: 24982101
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Successful management of an acute subdural hematoma in a patient dependent on continuous treprostinil infusion therapy.
    Safain M; Shepard M; Rahal J; Kryzanski J; Hwang S; Roguski M; Riesenburger RI
    J Neurosurg; 2013 Apr; 118(4):753-6. PubMed ID: 23373804
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treprostinil for the treatment of pulmonary hypertension.
    Skoro-Sajer N; Lang I
    Expert Opin Pharmacother; 2008 Jun; 9(8):1415-20. PubMed ID: 18473715
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treprostinil Administered to Treat Pulmonary Arterial Hypertension Using a Fully Implantable Programmable Intravascular Delivery System: Results of the DelIVery for PAH Trial.
    Bourge RC; Waxman AB; Gomberg-Maitland M; Shapiro SM; Tarver JH; Zwicke DL; Feldman JP; Chakinala MM; Frantz RP; Torres F; Cerkvenik J; Morris M; Thalin M; Peterson L; Rubin LJ
    Chest; 2016 Jul; 150(1):27-34. PubMed ID: 27396777
    [TBL] [Abstract][Full Text] [Related]  

  • 31. One-year experience with intravenous treprostinil for pulmonary arterial hypertension.
    Benza RL; Tapson VF; Gomberg-Maitland M; Poms A; Barst RJ; McLaughlin VV
    J Heart Lung Transplant; 2013 Sep; 32(9):889-96. PubMed ID: 23953817
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of switching from epoprostenol to IV treprostinil on treatment satisfaction and quality of life in patients with pulmonary hypertension.
    Minai OA; Parambil J; Dweik RA; Davila GH; Peterson L; Rollins KD; Chen H
    Respir Med; 2013 Mar; 107(3):458-65. PubMed ID: 23266038
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety, efficacy and Management of subcutaneous treprostinil infusions in the treatment of severe pediatric pulmonary hypertension.
    Levy M; Del Cerro MJ; Nadaud S; Vadlamudi K; Colgazier E; Fineman J; Bonnet D; Adatia I
    Int J Cardiol; 2018 Aug; 264():153-157. PubMed ID: 29650343
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Transition from intravenous to subcutaneous prostacyclin in pulmonary hypertension].
    Escribano Subías P; Cea-Calvo L; Tello de Menesses R; Gómez Sánchez MA; Delgado Jiménez JF; Sáenz de la Calzada C
    Rev Esp Cardiol; 2003 Aug; 56(8):818-21. PubMed ID: 12892628
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Totally Implantable IV Treprostinil Therapy in Pulmonary Hypertension Assessment of the Implantation Procedure.
    Waxman AB; McElderry HT; Gomberg-Maitland M; Burke MC; Ross EL; Bersohn MM; Pangarkar SS; Tarver JH; Zwicke DL; Feldman JP; Chakinala MM; Frantz RP; Thompson GB; Torres F; Rauck RL; Clagg K; Durst L; Li P; Morris M; Southall KL; Peterson L; Bourge RC
    Chest; 2017 Dec; 152(6):1128-1134. PubMed ID: 28583617
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Extended-release oral treprostinil in the management of pulmonary arterial hypertension: clinical evidence and experience.
    Coons JC; Miller T
    Ther Adv Respir Dis; 2018; 12():1753466618766490. PubMed ID: 29609511
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension.
    McLaughlin VV; Gaine SP; Barst RJ; Oudiz RJ; Bourge RC; Frost A; Robbins IM; Tapson VF; McGoon MD; Badesch DB; Sigman J; Roscigno R; Blackburn SD; Arneson C; Rubin LJ; Rich S;
    J Cardiovasc Pharmacol; 2003 Feb; 41(2):293-9. PubMed ID: 12548091
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Subcutaneous treprostinil was effective and tolerable in a patient with severe pulmonary hypertension associated with chronic kidney disease on hemodialysis.
    Watanabe T; Abe K; Horimoto K; Hosokawa K; Ohtani K; Tsutsui H
    Heart Lung; 2017; 46(2):129-130. PubMed ID: 28189266
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial.
    Tapson VF; Gomberg-Maitland M; McLaughlin VV; Benza RL; Widlitz AC; Krichman A; Barst RJ
    Chest; 2006 Mar; 129(3):683-8. PubMed ID: 16537868
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An implantable pump Lenus pro® in the treatment of pulmonary arterial hypertension with intravenous treprostinil.
    Kurzyna M; Małaczyńska-Rajpold K; Koteja A; Pawlak A; Chrzanowski Ł; Furdal M; Gąsior Z; Jacheć W; Sobkowicz B; Norwa J; Mularek-Kubzdela T; Torbicki A
    BMC Pulm Med; 2017 Dec; 17(1):162. PubMed ID: 29195500
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.